WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT04551456

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04551456
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04551456. Randomized; double masking; primary purpose treatment. Start 2020-11-30 (anticipated); primary completion 2021-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease
Acronym
WANICHD
Intervention (Biological)
Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Lead sponsor
Navy General Hospital, Beijing (class: other)
Collaborator
Chinese PLA General Hospital (class: other)
Collaborator
Peking University Third Hospital (class: other)
Collaborator
Peking Union Medical College Hospital (class: other)
Collaborator
Xijing Hospital (class: other)

Record details

Record id
cardio:ct-nct04551456
Content hash
c3c2b6016bae07562b3237ad0fe147d848b6457bada83c1ebb216da20fd8081c